Format

Send to

Choose Destination
J Am Acad Dermatol. 2012 Dec;67(6):e249-52. doi: 10.1016/j.jaad.2011.06.022. Epub 2011 Oct 19.

Mucosal manifestations of pemphigus vulgaris in ear, nose, and throat; before and after treatment.

Author information

1
Skin Research Center, Shahid Beheshti University of Medical Sciences, Shohada-e Tajrish Hospital, Tehran, Iran. rmrobati@gmail.com

Abstract

BACKGROUND:

Pemphigus vulgaris (PV) is a life-threatening autoimmune bullous disease, mediated by autoantibodies directed against antigens on the keratinocyte cell surface of stratified squamous epithelia. The frequency of ear, nose, and throat (ENT) involvement in PV is not clearly identified.

OBJECTIVE:

We sought to evaluate the ENT involvement in new patients with PV examined by ENT endoscopy before and after treatment.

METHODS:

This study included 41 new patients with PV. All patients were evaluated for ENT manifestations by otoscopic and endoscopic examination before treatment. After these examinations, the patients received proper treatment according to standard protocols. Thirty patients were re-evaluated by endoscopic examination after clinical remission of mucocutaneous signs.

RESULTS:

A total of 41 (33 [80.5%] male and 8 [19.5%] female) patients with mean age of 44.56 ± 12.76 years entered this study. In ENT examination of patients before the treatment, 11 (26.8%) patients showed ear, 15 (36.6%) nasal, 37 (90.3%) oral, 25 (61%) pharyngeal, and 24 (58.5%) laryngeal involvement. Thirty patients underwent the posttreatment ENT examination. We found ear signs in 2 (6.7%), nasal involvement in 1 (3.3%), oral signs in 4 (13.3%), pharyngeal manifestations in 6 (20%), and laryngeal signs in 3 (10%) patients after treatment. The treatment was significantly effective in the improvement of mucosal lesion in different sites (P < .01).

LIMITATION:

Eleven patients refused to undergo posttreatment ENT examination.

CONCLUSION:

ENT evaluation may be worthwhile to evaluate the disease extension in patients with PV more definitely and exclude other potential etiologies in recalcitrant patients.

PMID:
22015151
DOI:
10.1016/j.jaad.2011.06.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center